T-BRIDGE Trademark

Trademark Overview


On Wednesday, July 12, 2023, a trademark application was filed for T-BRIDGE with the United States Patent and Trademark Office. The USPTO has given the T-BRIDGE trademark a serial number of 98081112. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, December 24, 2024. This trademark is owned by T-Therapeutics Limited. The T-BRIDGE trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposes, namely, for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors...

Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNA, genetics, and genetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes

Scientific and technological services, namely, scientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infections, cancer, disease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering for protection and prevention from infections, cancer, disease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical...
t-bridge

General Information


Serial Number98081112
Word MarkT-BRIDGE
Filing DateWednesday, July 12, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, December 24, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 24, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposes, namely, for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposes, namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; immunotherapeutic drugs namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes
Goods and ServicesMedical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNA, genetics, and genetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes
Goods and ServicesScientific and technological services, namely, scientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infections, cancer, disease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering for protection and prevention from infections, cancer, disease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibiotics; research and development of microorganisms and cells in the nature of guided nuclease-based biocides; scientific research in the nature of conducting clinical trials for pharmaceutical products for others; bacteriological research; scientific research for medical purposes in the field of viruses and viral diseases; biological research; scientific screening and assaying being drug screening for scientific research purposes; chemical analysis; chemical research; DNA screening for scientific research purposes; genetic testing of laboratory animals for research purposes; biochemical engineering services being biochemical research and development; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of pharmaceuticals and scientific research consulting in the field of pharmaceuticals

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 10, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 10, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, August 10, 2023
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameT-Therapeutics Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCambridge CB216AL
GB

Party NameT-Therapeutics Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCambridge CB216AL
GB

Trademark Events


Event DateEvent Description
Saturday, July 15, 2023NEW APPLICATION ENTERED
Thursday, August 10, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, March 20, 2024ASSIGNED TO EXAMINER
Saturday, March 23, 2024NON-FINAL ACTION WRITTEN
Saturday, March 23, 2024NON-FINAL ACTION E-MAILED
Saturday, March 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 27, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, March 27, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, March 27, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, May 31, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, May 31, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, May 31, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, June 11, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 11, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 11, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, July 10, 2024NON-FINAL ACTION WRITTEN
Wednesday, July 10, 2024NON-FINAL ACTION E-MAILED
Wednesday, July 10, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, October 9, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 9, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 9, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 13, 2024FINAL REFUSAL WRITTEN
Wednesday, November 13, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, November 13, 2024FINAL REFUSAL E-MAILED
Friday, November 22, 2024EXAMINERS AMENDMENT E-MAILED
Friday, November 22, 2024EXAMINER'S AMENDMENT ENTERED
Friday, November 22, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, November 22, 2024EXAMINERS AMENDMENT -WRITTEN
Tuesday, November 26, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 18, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 24, 2024PUBLISHED FOR OPPOSITION
Tuesday, December 24, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED